KRAS and neoplasm: Clinical evaluation has reported altered levels of several different miRNAs, including miR-21, miR-212, miR-7, miR-608, miR-198, etc. in non-small-cell lung cancer (NSCLC) patients16 and in A549 lung cancer cells,17, 20, 21 miRNAs associated with tumor migration, invasion and angiogenic properties have been identified.20 However, similar studies have not been performed on SK-LU-1 cells, which possess the KRAS G12D mutation and have mutated p53 expression.